Search - tctmd.com

Displaying 21 - 40 of 47

Sort: Relevancy | Date

News Industry News

Boston Scientific Announces First U.S. Commercial Procedures With The WATCHMAN™ Left Atrial Appendage Closure Device

March 24, 2015

News Industry News

Boston Scientific Receives FDA Approval for WATCHMAN™ Left Atrial Appendage Closure Device

March 13, 2015

News Industry News

New Study Evaluates “Triple Therapy” Regimens After Drug-Eluting Stenting in Patients Requiring Oral Anticoagulation

September 15, 2014

News Industry News

Subgroup Analysis of ENGAGE AF-TIMI 48 Explores the Relationship Between Edoxaban Dose, Concentration, Anti-Factor Xa Activity and Outcomes

September 02, 2014

News Industry News

Efficacy and Safety Profile of Pradaxa® (dabigatran etexilate) Repeatedly Confirmed

July 23, 2014

News Industry News

Bristol-Myers Squibb and Pfizer Announce Enrollment of First Patient in Phase IV EMANATE Trial to Assess Effectiveness and Safety of Eliquis® (apixaban) in Patients with NVAF Undergoing Cardioversion

July 17, 2014

News Industry News

Cook Medical begins two studies on inferior vena cava filters

June 02, 2014

News Industry News

New study to investigate dabigatran etexilate for prevention of recurrent stroke in high-risk patients

May 07, 2014

News Industry News

New Pradaxa® (dabigatran etexilate mesylate) Data to be Presented at American College of Cardiology Scientific Session (ACC.14)

March 24, 2014

News Industry News

New Four-Year Data From Boston Scientific Demonstrated WATCHMAN® Device Was Superior To Warfarin For Mortality And Primary Efficacy In Patients With Atrial Fibrillation In Long Term Follow-Up Of The P

May 09, 2013

News Industry News

World’s First Pulmonary Embolism Trial Comparing Endovascular Therapy to Standard of Care

March 08, 2013

News Industry News

Data from St. Jude Medical RESPECT Trial for PFO Closure Highlighted at International Stroke Conference 2013

February 07, 2013

News Industry News

Clinical Trial Shows that PFO Closure With Investigational Device Does Not Decrease Ischemic and Bleeding Events Compared to Medical Therapy

October 25, 2012

News Industry News

Boston Scientific WATCHMAN® Left Atrial Appendage Closure Device Receives CE Mark Approval For Expanded Use

August 26, 2012

News Industry News

Boston Scientific Completes Patient Enrollment in PREVAIL Study for First-in-Class WATCHMAN Device

July 02, 2012

News Industry News

Study of First-in-Class WATCHMAN® Device Shows 75 Percent Reduction in Stroke Risk in Patients with Atrial Fibrillation Not Eligible for Oral Anticoagulation Therapy

May 11, 2012

News Industry News

Boston Scientific's WATCHMAN® Device Implanted in First Patients in Latin America

November 15, 2011

News Industry News

FDA Approves XARELTO® (rivaroxaban) to Reduce the Risk of Stroke and Systemic Embolism in Patients with Nonvalvular Atrial Fibrillation

November 04, 2011

News Industry News

Emboline, Inc. to Debut Game-Changing Embolic Protection Technology for Percutaneous Heart Valve Procedures in San Francisco Next Week

November 02, 2011

News Industry News

FDA Advisory Committee Recommends Approval of Oral Anticoagulant Rivaroxaban for the Prevention of Stroke and Systemic Embolism in Patients with Non-Valvular Atrial Fibrillation

September 08, 2011

Advertisement

Boston Scientific Announces First U.S. Commercial Procedures With The WATCHMAN™ Left Atrial Appendage Closure Device

Boston Scientific Receives FDA Approval for WATCHMAN™ Left Atrial Appendage Closure Device

New Study Evaluates “Triple Therapy” Regimens After Drug-Eluting Stenting in Patients Requiring Oral Anticoagulation

Subgroup Analysis of ENGAGE AF-TIMI 48 Explores the Relationship Between Edoxaban Dose, Concentration, Anti-Factor Xa Activity and Outcomes

Efficacy and Safety Profile of Pradaxa® (dabigatran etexilate) Repeatedly Confirmed

Bristol-Myers Squibb and Pfizer Announce Enrollment of First Patient in Phase IV EMANATE Trial to Assess Effectiveness and Safety of Eliquis® (apixaban) in Patients with NVAF Undergoing Cardioversion

Cook Medical begins two studies on inferior vena cava filters

New study to investigate dabigatran etexilate for prevention of recurrent stroke in high-risk patients

New Pradaxa® (dabigatran etexilate mesylate) Data to be Presented at American College of Cardiology Scientific Session (ACC.14)

New Four-Year Data From Boston Scientific Demonstrated WATCHMAN® Device Was Superior To Warfarin For Mortality And Primary Efficacy In Patients With Atrial Fibrillation In Long Term Follow-Up Of The P

World’s First Pulmonary Embolism Trial Comparing Endovascular Therapy to Standard of Care

Data from St. Jude Medical RESPECT Trial for PFO Closure Highlighted at International Stroke Conference 2013

Clinical Trial Shows that PFO Closure With Investigational Device Does Not Decrease Ischemic and Bleeding Events Compared to Medical Therapy

Boston Scientific WATCHMAN® Left Atrial Appendage Closure Device Receives CE Mark Approval For Expanded Use

Boston Scientific Completes Patient Enrollment in PREVAIL Study for First-in-Class WATCHMAN Device

Study of First-in-Class WATCHMAN® Device Shows 75 Percent Reduction in Stroke Risk in Patients with Atrial Fibrillation Not Eligible for Oral Anticoagulation Therapy

Boston Scientific's WATCHMAN® Device Implanted in First Patients in Latin America

FDA Approves XARELTO® (rivaroxaban) to Reduce the Risk of Stroke and Systemic Embolism in Patients with Nonvalvular Atrial Fibrillation

Emboline, Inc. to Debut Game-Changing Embolic Protection Technology for Percutaneous Heart Valve Procedures in San Francisco Next Week

FDA Advisory Committee Recommends Approval of Oral Anticoagulant Rivaroxaban for the Prevention of Stroke and Systemic Embolism in Patients with Non-Valvular Atrial Fibrillation

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content